Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GILD 
Gilead Sciences Inc (GILD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: GILD (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
30 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $124.79
1 Year Target Price $124.79
| 15 | Strong Buy |
| 4 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.85% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 142.13B USD | Price to earnings Ratio 22.74 | 1Y Target Price 124.79 |
Price to earnings Ratio 22.74 | 1Y Target Price 124.79 | ||
Volume (30-day avg) 30 | Beta 0.38 | 52 Weeks Range 79.46 - 120.99 | Updated Date 09/16/2025 |
52 Weeks Range 79.46 - 120.99 | Updated Date 09/16/2025 | ||
Dividends yield (FY) 2.74% | Basic EPS (TTM) 4.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 21.87% | Operating Margin (TTM) 39.16% |
Management Effectiveness
Return on Assets (TTM) 12.62% | Return on Equity (TTM) 33.4% |
Valuation
Trailing PE 22.74 | Forward PE 13.23 | Enterprise Value 161867432227 | Price to Sales(TTM) 4.92 |
Enterprise Value 161867432227 | Price to Sales(TTM) 4.92 | ||
Enterprise Value to Revenue 5.61 | Enterprise Value to EBITDA 14.76 | Shares Outstanding 1240809984 | Shares Floating 1238163997 |
Shares Outstanding 1240809984 | Shares Floating 1238163997 | ||
Percent Insiders 0.1 | Percent Institutions 90.75 |
Upturn AI SWOT
Gilead Sciences Inc
Company Overview
History and Background
Gilead Sciences Inc. was founded in 1987. Initially focused on antiviral research, it has become a leading biopharmaceutical company known for its treatments for HIV, hepatitis, and other life-threatening diseases. Key milestones include the development of Tamiflu, Truvada, and Sovaldi.
Core Business Areas
- HIV: Develops and commercializes therapies for the treatment and prevention of HIV infection. This is a major revenue driver.
- Liver Diseases: Focuses on therapies for chronic liver diseases, including hepatitis B (HBV) and hepatitis C (HCV), as well as for liver cancer.
- Oncology: Develops and commercializes therapies for various types of cancer, including hematological malignancies and solid tumors.
- Other: Includes other therapeutic areas such as cell therapy and inflammatory diseases.
Leadership and Structure
Daniel O'Day is the Chairman and Chief Executive Officer. The company has a traditional hierarchical structure with various departments focusing on research, development, commercialization, and operations.
Top Products and Market Share
Key Offerings
- Biktarvy: A leading HIV treatment. Its market share is significant in the HIV treatment space. Competitors include GSK's Dovato and ViiV Healthcare products. Generated $10.9 billion in revenue in 2023.
- Descovy: An HIV treatment for PrEP (pre-exposure prophylaxis). Competes with Truvada and Apretude from ViiV Healthcare. Revenue of $2.0 billion in 2023.
- Veklury (Remdesivir): An antiviral medication used to treat COVID-19. Competitors include Pfizer's Paxlovid. Generated $2.2 billion in revenue in 2023.
- Trodelvy: A treatment for metastatic triple-negative breast cancer. Faces competition from other targeted therapies. Revenue of $0.87 billion in 2023.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with a focus on developing and commercializing innovative therapies. Growth is driven by aging populations, increasing healthcare spending, and advancements in medical technology.
Positioning
Gilead Sciences Inc. is a major player in the biopharmaceutical industry, with a strong focus on antiviral therapies and a growing presence in oncology. Its competitive advantages include its established product portfolio, strong research and development capabilities, and strategic acquisitions.
Total Addressable Market (TAM)
The biopharmaceutical market is estimated to be worth over $1.5 trillion globally. Gilead Sciences Inc. is positioned to capture a significant portion of this TAM through its existing products and pipeline of new therapies.
Upturn SWOT Analysis
Strengths
- Strong product portfolio in HIV and liver diseases
- Established brand reputation
- Robust research and development pipeline
- Experienced management team
- Significant cash reserves
Weaknesses
- Reliance on a few key products
- Patent expirations on key drugs
- Competition from generic drugs
- Dependence on acquisitions for growth
- HCV revenue decline
Opportunities
- Expansion into new therapeutic areas (e.g., oncology)
- Strategic acquisitions and partnerships
- Development of novel therapies
- Growing demand for biopharmaceuticals in emerging markets
- Advancements in personalized medicine
Threats
- Increasing competition from other biopharmaceutical companies
- Pricing pressures and healthcare reforms
- Regulatory hurdles and approval delays
- Generic erosion of key products
- Economic downturns
Competitors and Market Share
Key Competitors
- VRTX
- MRK
- BMY
- JNJ
- PFE
Competitive Landscape
Gilead Sciences Inc. faces intense competition from other major pharmaceutical companies, including Vertex, Merck, Bristol-Myers Squibb, Johnson & Johnson, and Pfizer. Its competitive advantages include its strong HIV franchise and growing oncology presence. Disadvantages include dependence on key products and patent expirations.
Major Acquisitions
Immunomedics
- Year: 2020
- Acquisition Price (USD millions): 21000
- Strategic Rationale: To acquire Trodelvy, a promising treatment for metastatic triple-negative breast cancer, expanding Gilead's oncology portfolio.
MYR GmbH
- Year: 2020
- Acquisition Price (USD millions): 1400
- Strategic Rationale: To gain access to Hepcludex (bulevirtide), a first-in-class entry inhibitor for the treatment of chronic hepatitis delta virus (HDV).
Growth Trajectory and Initiatives
Historical Growth: Gilead Sciences Inc. experienced significant growth in the past due to its HCV franchise, but growth has slowed in recent years due to patent expirations and increased competition.
Future Projections: Analysts project moderate revenue growth for Gilead Sciences Inc. in the coming years, driven by its HIV and oncology franchises. EPS growth is expected to be higher due to cost management and share repurchases.
Recent Initiatives: Recent initiatives include acquisitions in the oncology space (e.g., Immunomedics) and strategic partnerships to expand its pipeline.
Summary
Gilead Sciences Inc. is a strong biopharmaceutical company with a leading position in HIV and a growing presence in oncology. While it faces challenges from patent expirations and competition, its robust R&D pipeline and strategic acquisitions position it for future growth. The company should watch for regulatory changes and pricing pressures.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Gilead Sciences Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gilead Sciences Inc
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 1992-01-22 | Chairman & CEO Mr. Daniel P. O'Day | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 17600 | Website https://www.gilead.com |
Full time employees 17600 | Website https://www.gilead.com | ||
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.